Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-11-13
DOI
10.1002/ijc.32783
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
- (2016) Vicky Makker et al. CANCER
- Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
- (2016) Günter Emons et al. GYNECOLOGIC ONCOLOGY
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
- (2015) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma
- (2015) Ursula Matulonis et al. GYNECOLOGIC ONCOLOGY
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
- (2015) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of mTORC1 by PI3K signaling
- (2015) Christian C. Dibble et al. TRENDS IN CELL BIOLOGY
- Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
- (2015) Daniel H. Ahn et al. Scientific Reports
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
- (2014) T. A. Yap et al. CLINICAL CANCER RESEARCH
- Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
- (2014) Daliah Tsoref et al. GYNECOLOGIC ONCOLOGY
- Endometrial cancer: A review and current management strategies: Part II
- (2014) William M. Burke et al. GYNECOLOGIC ONCOLOGY
- Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
- (2014) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
- The Search Continues
- (2014) Larissa A. Meyer et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
- (2013) N Colombo et al. BRITISH JOURNAL OF CANCER
- Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
- (2013) I Ray-Coquard et al. BRITISH JOURNAL OF CANCER
- Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
- (2013) Helen J. Mackay et al. CANCER
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
- (2012) H. Liang et al. GENOME RESEARCH
- Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing
- (2012) Bojana Djordjevic et al. MODERN PATHOLOGY
- Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study
- (2012) Olivier Trédan et al. Targeted Oncology
- Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
- (2011) Amit M. Oza et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
- (2010) Brian M. Slomovitz et al. CANCER
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
- (2009) H. B. Salvesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More